Impact of 1st and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy:: Preliminary results of FIRST, a prospective community-based study

被引：0

作者：

Ozer, H

Mirtsching, B

Rader, M

Ding, B

Dansey, R

机构：

[1] Univ Oklahoma, Ctr Canc, Oklahoma City, OK USA

[2] Ctr Oncol Res & Treatment, Dallas, TX USA

[3] Hematol Oncol Rockland, New City, NY USA

[4] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：758S / 758S

页数：1

共 27 条

[21] Lifestyle Changes Observed among Adults Participating in a Family- and Community-Based Intervention for Diabetes Prevention in Europe: The 1st Year Results of the Feel4Diabetes-Study
Manios, Yannis
Lambrinou, Christina-Paulina
Mavrogianni, Christina
Cardon, Greet
Lindstrom, Jaana
Iotova, Violeta
Tankova, Tsvetalina
Rurik, Imre
Van Stappen, Vicky
Kivela, Jemina
Mateo-Gallego, Rocio
Moreno, Luis A.
Makrilakis, Konstantinos
Androutsos, Odysseas
NUTRIENTS, 2020, 12 (07) : 1 - 13
[22] Bevacizumab (bev) combined with chemotherapy as first-line treatment in patients (pts) with metastatic colorectal cancer: Final results from a large non-interventional, community-based study
Hildebrandt, B.
Bruch, H. -R
Zimber, J.
Hahn, L.
Lueck, A.
Timmer, H.
Kroening, H.
Tondar, S.
Kutscheidt, A.
Broszeit-Luft, S.
Oncology Research and Treatment, 2015, 38 : 205 - 206
[23] Bevacizumab (bev) combined with chemotherapy as first-line treatment in patients (pts) with advanced colorectal cancer: Final results from a large non-interventional community-based study
Hildebrandt, B.
Broszeit-Luft, S.
Bruch, H. R.
Zimber, J.
Hahn, L.
Lueck, A.
Kroening, H.
Tondar, S.
Kutscheidt, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S377 - S377
[24] FAILURE OF ALPHA-INTERFERON TO IMPROVE VMCP VBAP CHEMOTHERAPY RESPONSE RATE IN INDUCTION-PHASE OF UNTREATED MULTIPLE-MYELOMA - RESULTS IN THE 1ST 201 PATIENTS INCLUDED IN A PROSPECTIVE RANDOMIZED STUDY (KIF PROTOCOL)
CASASSUS, P
HAROUSSEAU, IL
MAHE, B
SADOUN, A
AUTRAND, B
BENBOUBKER, L
QUILICHINI, R
GARDEMBAS, A
MAISONNEUVE, H
SOTTO, JJ
PAYEN, C
OBERLING, F
FAIN, O
GHANDOUR, C
LAMY, T
BATAILLE, R
BLOOD, 1994, 84 (10) : A652 - A652
[25] Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)
Johnson, Bruce E.
Kim, Tae Min
Hiltermann, T. Jeroen N.
Barlesi, Fabrice
Grohe, Christian
Goto, Yasushi
Gunnarsson, Orvar
Overbeck, Tobias
Reguart, Noemi
Wermke, Martin
Castro, Gilberto
Felip, Enriqueta
Greystoke, Alastair
Solomon, Benjamin J.
Nebot, Noelia
Deudon, Stephanie
Louveau, Anne-Laure
Passos, Vanessa Q.
Tan, Daniel S. W.
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[26] RESULTS OF THE 1ST MULTICENTER AUSTRIAN OVARIAN-CANCER STUDY - PROSPECTIVE RANDOMIZED COMPARISON OF A SEQUENTIAL CHEMOTHERAPY (ADRIAMYCIN CISPLATIN-VINCRISTINE CYCLOPHOSPHAMIDE-METHOTREXATE) WITH 2 STANDARD TREATMENTS (ADRIAMYCIN CYCLOPHOSPHAMIDE OR ADRIAMYCIN CISPLATIN) IN PATIENTS WITH STAGE-III AND STAGE-IV CARCINOMAN
SALZER, H
GITSCH, E
DITTRICH, C
SEVELDA, P
KARRER, K
SCHEMPER, M
STEMPELSMEKAL, G
LANGER, M
WAGNER, G
RAINER, H
MOSER, K
CZERWENKA, K
BREITENECKER, G
SPONA, J
GEBURTSHILFE UND FRAUENHEILKUNDE, 1985, 45 (11) : 761 - 768
[27] CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC
Grohe, C.
Johnson, B. E.
Kim, T. M.
Hiltermann, T. J. N.
Barlesi, F.
Goto, Y.
Gunnarsson, O.
Overbeck, T.
Reguart, N.
Wermke, M.
de Castro, G., Jr.
Felip, E.
Greystoke, A.
Solomon, B. J.
Deudon, S.
Louveau, A. -L.
Passos, V.
Tan, D. S. W.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 152 - 152

← 1 2 3 →